Following our earlier findings, both AR agonists (DHT) and antagonists (Enz) may be potentially beneficial [15] in the treatment of ER + breast cancer, depends on the AR/ER ratio in the BC cells [15]. The gene discussed is ESR1; the disease is breast cancer.